Schweizerischer Nationalfonds / Fonds national suisse
Storys zum Thema Chemie
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
- mehr
Medison Pharma; Alnylam Pharmaceuticals
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
Zug, Switzerland (ots/PRNewswire) - - The expanded partnership will allow Alnylam and Medison to help accelerate access for patients in multiple regions under one global alliance - Medison, the creator and leader of the multi-regional partnership category, will utilize its unique, unified platform for efficient ...
mehrNorgine B.V. submits Marketing Authorisation Application via Project Orbis for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma
Amsterdam (ots/PRNewswire) - Norgine B.V. today announced its first marketing authorisation application submissions on 10 April 2024, seeking approval for eflornithine in high-risk neuroblastoma (HRNB), via Project Orbis in Australia, Switzerland and the United Kingdom. This milestone supports Norgine's efforts to ...
mehrAcousia Therapeutics attracts new investor on its path to make hearing loss a treatable disease
Tübingen (ots) - - German pioneer biotech accelerates hearing loss solution development with fresh capital boost Acousia Therapeutics GmbH, a clinical-stage biotech company developing drug candidates against acute and chronic forms of hearing loss, proudly announces Esperante Ventures as the latest addition to its esteemed group of investors. The infusion of fresh ...
mehrTakeda Pharma Vertrieb GmbH & Co. KG
The European Commission Approves Label Update for TAKHZYRO® (lanadelumab), Expanding Its Use to a Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (HAE)
Zurich (ots/PRNewswire) - - TAKHZYRO® is the First Routine Prevention Treatment of HAE Approved in the EU for Patients Under the Age of Six. - The therapeutical indication for TAKHZYRO® has been extended to patients aged 2 years and older.1 - Offers a New Preventative Treatment Option for young HAE patients with ...
mehrIpsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)
Zug, Switzerland and Paris (ots/PRNewswire) - Bylvay (odevixibat) is the first and only oral treatment available in Canada for the treatment of pruritus due to this rare genetic condition Today, Ipsen (Euronext: IPN) (ADR: IPSEY), a global biopharmaceutical company focused on transformative medicines in oncology, ...
mehrSoterios Pharma completes Phase II enrolment for STS-01 in mild / moderate (patchy) alopecia areata
London (ots/PRNewswire) - Soterios Pharma, a privately held clinical-stage pharmaceutical company, announced today that it has completed target enrolment for its Phase II trial with STS-01 for mild / moderate (patchy) alopecia areata. Final results of the study are anticipated to be available in Q2 2024. David Fleet, CEO of Soterios Pharma, said, "This represents an ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
Phosphorous - too much in lakes, too little in the soil
Bern (ots) - Over-fertilised waterways, impoverished soils: the use of phosphorous in agriculture is creating a dilemma, and it all began thousands of years ago. This has been verified by an analysis funded by the SNSF. It is well known that phosphorous from agricultural fertilisation and wastewater is harmful to lakes. But the entry of phosphorous into water is also contributing to the scarcity of this substance, which ...
mehr#Greentech: MECAWARE secures €40m to become the leader in battery recycling and the production of strategic metals in France and Europe
Lyon, France (ots/PRNewswire) - In order to speed up its industrial and commercial development, MECAWARE has secured €40 million from a pool of investors, the French government, under the auspices of the France 2030 plan, and its banking partners. This funding will enable the industrialisation of the pilot scheme ...
mehr- 4
Neustark launches the first commercial site for permanent CO₂ storage in the EU
mehr Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older
Zurich (ots/PRNewswire) - - If Approved, Lanadelumab Will be the First Long-Term Prophylactic Treatment of HAE Available in the EU for Patients Under the Age of Six. - Positive Opinion Based on Pivotal Study SHP643-301, Evaluating the Safety Profile and Pharmacokinetics (PK) of Lanadelumab, in Combination with ...
mehrHearing loss company Acousia Therapeutics to present key learnings and data from lead development programs at US and European meetings in August and September
Tübingen, Germany (ots) - Acousia Therapeutics GmbH to share key learnings and data from its lead candidate development programs — clinical stage ACOU085 and late preclinical stage ACOU082 — during four presentations at industry and research meetings from August 29 to September 5. From August 29–31, Acousia ...
mehrSuccessful FDA inspection at Aurisco's manufacturing site in Yangzhou, China
Yangzhou, China (ots/PRNewswire) - Aurisco Pharmaceutical today announced that its cGMP manufacturing plant in Yangzhou has successfully passed a USFDA inspection. Aurisco Pharmaceutical announced today that its API and FDF plant in Yangzhou, China has successfully passed a cGMP inspection by the US Food and Drug Administration (USFDA). The inspection, carried out by ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
Stacking - a route to higher-performance solid-state batteries
mehrGrünenthal and Kyowa Kirin International Announce Successful Completion of Deal to Enter Joint Venture Collaboration
Aachen, Germany and Tokyo, Japan (ots) - - The Joint Venture Collaboration includes a portfolio of 13 brands across six therapeutic areas, with the majority of revenue resulting from pain management medicines - The new enterprise will be branded as Grünenthal Meds. Grünenthal owns a 51 percent majority share and ...
mehr- 3
Neustark launches largest site for storing CO2 in demolition concrete
mehr Schweizerischer Nationalfonds / Fonds national suisse
The insatiable virus hunter
mehrArtilysin® - A Groundbreaking "Green Pharma" Solution
mehrD&A Pharma : Despite the latest alarming figures on alcohol dependence, France is delaying the use of sodium oxybate, which has been prescribed for almost 30 years in Italy and Austria
Paris (ots/PRNewswire) - At the beginning of June, the health authorities hammered it home once again: "The health, social and economic consequences of alcohol consumption represent a burden for French society." The results are alarming: every year in France, alcohol is the cause of 49,000 deaths and an estimated ...
mehrCroma-Pharma announces enrollment of first patient in hyaluronic acid dermal filler clinical trial in China
Vienna (ots/PRNewswire) - Croma-Pharma® ('Croma') announced today that in June the first patient will be enrolled in the clinical trial1 for the approval of its hyaluronic acid dermal filler Princess® Volume Plus Lidocaine2 in China. The randomised, multi-centre, evaluator blinded, parallel group, active ...
mehrCroma-Pharma: Launch of topical anaesthetic Pliaglis® in Europe
Vienna (ots/PRNewswire) - Croma-Pharma, a global player and challenger in the dynamically growing, minimally invasive aesthetics market, announces that it will launch Pliaglis®, a topical local anaesthetic for superficial dermatological procedures, in its European core markets including Germany, the United Kingdom ("UK"), and Ireland. Further markets including Brazil will follow by the end of 2023. The anaesthetic cream ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
The age of blood stains says more about the crime
Bern (ots) - The composition of blood stains changes over the course of weeks and months. Forensic medicine hopes to make use of this fact in future to convict suspects - or to prove their innocence. The blood-stained paper lay on the roof terrace for almost a year, protected from the rain but otherwise exposed to the elements. Fortunately it wasn't evidence of a violent crime; no, the drops of blood were part of a ...
mehrAmicogen and Lysando: Novel approach for the treatment of mastitis in dairy cows
mehrHovione and H&T Presspart extend partnership to advance high efficiency device technology for Dry Powder Inhalation formulation delivery
Lisbon, Portugal (ots/PRNewswire) - Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and H&T Presspart have entered in a strategic partnership to advance the development of Presspart's Sunriser© Capsule-based Dry Powder Inhaler platform. The demand for inhalable drugs that ...
mehrAurisco Expands Oligonucleotide Capacity and Launches New Website
SETÚBAL, Portugal (ots/PRNewswire) - The New State-of-Art OligoPilot 2000™ solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs. The new website shows how R&D and Innovation is the driving force of its sustainable growth, featuring its technologies, capabilities, services and products, including Oligonucleotides, peptides and small molecules ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
If paradise were made of concrete
mehrAurisco Expands Oligonucleotide Capacity and Launches New Website
SETÚBAL, Portugal (ots/PRNewswire) - The New State-of-Art OligoPilot 2000TM solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs. The new website shows how R&D and Innovation is the driving force of its sustainable growth, featuring its technologies, capabilities, services and products, including Oligonucleotides, peptides and small molecules ...
mehrHovione and Ripple Enter Strategic Partnership to Expand Epidel® Platform into Non-Ophthalmic Space
Lisbon, Portugal (ots/PRNewswire) - Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and Ripple Therapeutics, a leading ophthalmic sustained drug delivery company, have entered a strategic partnership to expand the use of Ripple's Epidel® platform beyond ophthalmic applications. The core feature of Ripple's Epidel® technology ...
mehrMedison Pharma; Alnylam Pharmaceuticals
Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics
Zug, Switzerland (ots/PRNewswire) - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies for patients in international markets, have announced an expansion of their ...
mehrIktos raises € 15.5m Series A round to expand its artificial intelligence-based drug discovery technologies and solutions
Paris, France and Lausanne Switzerland (ots) - ● The round is co-led by M Ventures and Debiopharm Innovation Fund with Omnes Capital; all joining as new investors ● Series A will enable Iktos to expand its AI technology platform and launch Iktos Robotics; an AI-driven automated end-to-end drug discovery service ...
mehr